Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the prevalence of male androgenetic alopecia in a Singapore community was 63%, increasing with age and showing higher rates among Indians compared to Chinese.

This review discusses the potential of antiandrogens for androgen-induced baldness in men and women but reports no new clinical findings, emphasizing the need for further research on long-term risks and efficacy.

This article reviews scalp flap surgery for hair restoration, emphasizing its ability to provide immediate and natural hair coverage compared to traditional hair transplantation, and reports no new clinical results.

This study found that men with early-onset androgenetic alopecia and certain risk factors may have worse gonadal steroidogenesis and an increased likelihood of developing gonadal dysfunction, suggesting a male equivalent of polycystic ovarian syndrome.

This perspective highlights the role of inflammation in male and female pattern hair loss and its implications for developing future therapeutic options.

This study found that platelet-rich plasma injections significantly increased hair density in men with androgenetic alopecia compared to placebo, but further research is needed to understand factors influencing treatment success.

This meta-analysis suggests that individuals with vertex baldness may have a higher risk of prostate cancer, though overall baldness is not significantly associated with prostate cancer risk.

This review discusses various classification systems for male-pattern hair loss, comparing their detail, practicality, and reproducibility, and reports no new clinical outcomes.

This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.

In this study, untreated men with androgenetic alopecia continued to experience progressive hair loss over a 5-year period, with a significant decline in hair density observed in the placebo group.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This study found differences in urinary androgen and estrogen concentrations between male pattern baldness patients treated with finasteride and healthy controls, suggesting potential biomarkers for post-finasteride syndrome.

This study found an association between dispensed finasteride and an increased risk of male breast cancer, though uncertainties around confounding factors and potential biases suggest these results should be interpreted with caution.

In this exploratory study, researchers found slightly increased levels of inflammatory markers in scalp skin affected by androgenetic alopecia, suggesting differential gene expression involved in hair cycle and keratin production.

This study found that males with androgenetic alopecia had a significantly lower 2D:4D digit length ratio in the right hand compared to healthy controls, which may indicate prenatal androgen exposure.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.

This review summarizes the characteristics of the peri-malignant melanoma stroma, indicating its potential role in early dermal metastatic migration and increased metastasis risk.

This study found that antifungal therapy significantly reduced pustules in patients with refractory acne, indicating a potential role for Malassezia infection in such cases.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

In this study, ultraviolet light did not significantly enhance or worsen hair growth induced by topical minoxidil in men with male pattern baldness.

This case report describes a 35-year-old man with Malassezia folliculitis occurring alongside granuloma annulare and alopecia areata, which had not been previously documented together.

This article discusses scalp reduction as a technique in male pattern baldness, highlighting its potential to enhance hair transplantation outcomes, but reports no new clinical results.

This study observed that multinucleate giant cells were present in 31% of biopsy specimens from patients with male pattern alopecia but not in other alopecia types, suggesting a potential histologic marker for androgenetic alopecia.

In this study, researchers observed that Malassezia species show different lipid metabolism and growth patterns depending on pH, with slightly acidic conditions promoting beneficial lipid bio-conversion for skin health, while neutral pH resulted in lower growth and lipid content, potentially negatively impacting the skin.

This research found that Leydig cells significantly rely on synthesizing omega-6 HUFAs to support male steroid hormone production, highlighting a new role for these fatty acids in the male reproductive system.

This study found no evidence that finasteride use is associated with an increased risk of male breast cancer.

This article reviews the genetic research on male androgenetic alopecia, highlighting that over 300 associated risk variants have been identified, with unclear mechanisms of action.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study found that t-flavanone may promote hair growth in people with androgenic alopecia by enhancing hair anchoring strength and upregulating desmoglein expression in hair follicles over 30 weeks.